

AS8351

Cat. No.: HY-100744 CAS No.: 796-42-9 Molecular Formula: $C_{17}H_{13}N_3O_2$

Molecular Weight: 291.3

Histone Demethylase Target:

Pathway: **Epigenetics**

Storage: Powder -20°C 3 years

4°C 2 years

-80°C In solvent 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 150 mg/mL (514.93 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.4329 mL	17.1644 mL	34.3289 mL
	5 mM	0.6866 mL	3.4329 mL	6.8658 mL
	10 mM	0.3433 mL	1.7164 mL	3.4329 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.58 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	AS8351 (NSC51355) is a KDM5B inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells ^[1] .
IC & Target	KDM5

IC₅₀ & Target

AS8351 affects epigenetic modifications by competing with α -ketoglutarate (α -KG) for chelating iron [Fe(II)] in certain $epigenetic\ enzymes, such\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ \alpha\text{-}KG\ and\ iron\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ \alpha\text{-}KG\ and\ iron\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ \alpha\text{-}KG\ and\ iron\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ \alpha\text{-}KG\ and\ iron\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ \alpha\text{-}KG\ and\ iron\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ \alpha\text{-}KG\ and\ iron\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ \alpha\text{-}KG\ and\ iron\ as\ the\ JmjC\ domain-containing\ histone\ demethylases\ (JmjC-KDMs)\ that\ require\ and\ another that\ another\ that\ ano$ co-factors^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

In Vitro

[1]. Liu K, et al. Chemical Modu	lation of Cell Fate in Stem Cell T	herapeutics and Regenerative	Medicine. Cell Chem Biol. 2016 Aug	18;23(8):893-916.
[2]. Cao N, et al. Conversion of I	human fibroblasts into function	al cardiomyocytes by small me	olecules. Science. 2016 Jun 3;352(62	290):1216-20.
	Caution: Product has not I	been fully validated for me	dical applications. For research	use only.
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExp	press.com
	Address: 1 De	eer Park Dr, Suite Q, Monmo	uth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com